CRISPR Therapeutics AG (CRSP) 股票分析

公司概述

CRISPR Therapeutics AG operates as a specialized gene editing company dedicated to developing gene-based medicines aimed at treating serious human diseases. The firm leverages its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform, which serves as a precise technology for gene editing applications. This biotechnology entity functions within the Healthcare sector and specifically targets the Biotechnology industry, focusing on the creation of novel therapeutic interventions. With a market capitalization of $4.96B and trailing twelve-month revenue of $3.51M, the company's scale reflects significant investor valuation despite minimal reported revenue. The disparity between its multi-billion dollar market cap and low annual revenue indicates that the market price primarily values the company's intellectual property, future pipeline potential, and long-term clinical prospects rather than current earnings generation. Although specific employee count data is unavailable, the operational scope suggests a capital-intensive research environment typical of advanced biotech firms.

财务健康

The company reported annual revenue of $3.51M for the trailing twelve months, yet generated a net income of -$581,598,976, revealing a substantial gap where operating costs and research expenditures vastly exceed current sales. This negative net income alongside an EBITDA of -$548,838,976 highlights a cost structure dominated by high upfront investments in clinical trials and drug development rather than profitable operations. Free cash flow stands at -$205,623,744, indicating that the company is burning cash and lacks immediate financial flexibility to fund operations without external capital injections. The gross margin is recorded at 0.0%, while the operating margin reaches a negative 17912.5% and profit margin is 0.0%, figures that collectively signal the entity is not yet commercially viable and is in a heavy investment phase. On the balance sheet, the company holds $1.98B in cash against $206.75M in debt, creating a conservative liquidity position where cash assets significantly outweigh liabilities. The debt-to-equity ratio of 10.76 suggests a high level of leverage relative to equity, yet this is mitigated by the massive cash reserve preventing default risk. Additionally, a current ratio of 13.32 demonstrates exceptional short-term liquidity, meaning the firm possesses more than thirteen times the current assets necessary to cover its current liabilities. Return on Equity stands at -30.2% and Return on Assets is -15.8%, metrics that reveal management is currently deploying capital to generate future value rather than delivering immediate shareholder returns.

估值评估

The valuation metrics present a complex picture, with a trailing P/E ratio of N/A due to negative earnings and a forward P/E of -12.35, implying that analysts do not expect normalized earnings in the near term but rather a continued period of investment-driven losses. The price-to-book ratio is 2.58, indicating that the market values the company at 2.58 times its net asset book value, suggesting a premium assigned to its intangible assets and growth potential. Alternative valuation measures like a price-to-sales ratio of 1414.35 and an EV/EBITDA of -5.82 further underscore that traditional profitability-based valuation models are inapplicable for this stage of the company's lifecycle. The stock price has fluctuated significantly over the past year, trading between a 52-week high of $78.48 and a 52-week low of $30.52. To determine the current position relative to this range, one must calculate the percentage difference; without the current price explicitly stated in the facts, the precise percentage below the high cannot be calculated, but the wide range of $47.96 demonstrates high volatility inherent to early-stage biotech stocks. The beta value of 1.79 indicates that the stock's price volatility is nearly double that of the broader market, reflecting the heightened risk and sensitivity to sector-specific developments.

Growth & Income

Revenue growth year-over-year is reported at -97.6%, while earnings growth is listed as N/A due to the lack of profitability in the trailing twelve months. The decline in revenue combined with N/A earnings growth implies that the company is likely undergoing a transition period, possibly involving commercialization challenges or significant shifts in its sales model that prevent consistent year-over-year expansion. Regarding income, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This absence of dividend distribution confirms that the firm reinvests all available resources, including its substantial cash reserves, directly into research and development to sustain its long-term growth trajectory. Consequently, the overall growth and income profile is characterized by negative current revenue momentum and a complete absence of income generation, relying entirely on future clinical successes and market adoption to reverse these trends.